Arbutus Biopharma Corpora...

3.29
-0.05 (-1.50%)
At close: Apr 25, 2025, 3:59 PM
3.35
1.82%
After-hours: Apr 25, 2025, 05:55 PM EDT

Arbutus Biopharma Statistics

Share Statistics

Arbutus Biopharma has 191.48M shares outstanding. The number of shares has increased by 1.46% in one year.

Shares Outstanding 191.48M
Shares Change (YoY) 1.46%
Shares Change (QoQ) 1.05%
Owned by Institutions (%) 55.04%
Shares Floating 148.63M
Failed to Deliver (FTD) Shares 1.64K
FTD / Avg. Volume 0.16%

Short Selling Information

The latest short interest is 9.85M, so 5.14% of the outstanding shares have been sold short.

Short Interest 9.85M
Short % of Shares Out 5.14%
Short % of Float 6.51%
Short Ratio (days to cover) 10.25

Valuation Ratios

The PE ratio is -8.68 and the forward PE ratio is -32.45. Arbutus Biopharma's PEG ratio is 0.64.

PE Ratio -8.68
Forward PE -32.45
PS Ratio 98.35
Forward PS 3.7
PB Ratio 6.23
P/FCF Ratio -9.36
PEG Ratio 0.64
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Arbutus Biopharma.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 8.15, with a Debt / Equity ratio of 0.01.

Current Ratio 8.15
Quick Ratio 8.15
Debt / Equity 0.01
Debt / EBITDA -0.02
Debt / FCF -0.02
Interest Coverage -557.07

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $140.25K
Profits Per Employee $-1.59M
Employee Count 44
Asset Turnover 0.05
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by 22.06% in the last 52 weeks. The beta is 1.45, so Arbutus Biopharma's price volatility has been higher than the market average.

Beta 1.45
52-Week Price Change 22.06%
50-Day Moving Average 3.3
200-Day Moving Average 3.6
Relative Strength Index (RSI) 54.15
Average Volume (20 Days) 1.02M

Income Statement

In the last 12 months, Arbutus Biopharma had revenue of 6.17M and earned -69.92M in profits. Earnings per share was -0.38.

Revenue 6.17M
Gross Profit 6.17M
Operating Income -76.32M
Net Income -69.92M
EBITDA -68.4M
EBIT -69.78M
Earnings Per Share (EPS) -0.38
Full Income Statement

Balance Sheet

The company has 36.33M in cash and 1.29M in debt, giving a net cash position of 35.04M.

Cash & Cash Equivalents 36.33M
Total Debt 1.29M
Net Cash 35.04M
Retained Earnings 0
Total Assets 131.71M
Working Capital 111.7M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -64.85M and capital expenditures 0, giving a free cash flow of -64.85M.

Operating Cash Flow -64.85M
Capital Expenditures 0
Free Cash Flow -64.85M
FCF Per Share -0.35
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -1236.74% and -1133.04%.

Gross Margin 100%
Operating Margin -1236.74%
Pretax Margin -1133.04%
Profit Margin -1133.04%
EBITDA Margin -1108.46%
EBIT Margin -1236.74%
FCF Margin -1050.88%

Dividends & Yields

ABUS does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for ABUS is $5, which is 50.6% higher than the current price. The consensus rating is "Buy".

Price Target $5
Price Target Difference 50.6%
Analyst Consensus Buy
Analyst Count 4
Stock Forecasts

Stock Splits

The last stock split was on Nov 4, 2010. It was a backward split with a ratio of 1:5.

Last Split Date Nov 4, 2010
Split Type backward
Split Ratio 1:5

Scores

Altman Z-Score -4.02
Piotroski F-Score 4